Skip to content
LATEST
Health

Hormone Therapy and Semaglutide Combination Linked to Increased Weight Loss

Research suggests combining menopause hormone therapy with semaglutide may improve weight loss, though experts advise caution.

Hormone Therapy and Semaglutide Combination Linked to Increased Weight Loss

A study of 3,855 women indicates that the concurrent use of menopause hormone therapy (MHT) and semaglutide is associated with significantly greater weight loss compared to semaglutide monotherapy. Participants using the combined regimen demonstrated sustained weight reduction at 9, 12, and 15-month intervals, with a higher probability of achieving 30% total body weight loss.

In contrast, the study observed only modest, non-sustained weight loss differences when MHT was combined with tirzepatide. Researchers noted that these findings are based on observational data and have not yet undergone peer review.

Medical experts emphasize that MHT is currently FDA-approved for managing menopause symptoms rather than obesity. Clinical guidance suggests that treatment decisions should remain individualized based on patient medical history and specific health goals, rather than utilizing MHT as a primary weight loss intervention. Further randomized, prospective studies are required to establish a causal link between hormone therapy and enhanced GLP-1 efficacy.

More stories

Latest news